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A 33 year old woman presented in May of 2011 with chief com-
plaints of abdominal distention and pain. A past history of cone biopsy
of the cervix in 2002 showed pre-cancerous cells with no invasive
malignancy. CT of the chest, abdomen, and pelvis showed a large vol-
ume of intraabdominal ﬂuid consistent with combined mucinous and
serous ascites (Fig. 1). Laparoscopy was performed showing bilateral
adnexal masses, copious mucinous ﬂuid, and peritoneal metastases on
the abdominal wall, the right hemidiaphragm, and greater omentum.
Pathology showed mucinous adenocarcinoma and immunostains sug-
gested a cervical origin with P16 and CK7 positive and CK20 negative.Introduction
Pseudomyxoma peritonei is a clinical condition characterized
by mucinous tumors and mucinous ascites that accumulates in large
volume and over time will interrupt gastrointestinal function.
Pseudomyxoma peritonei most commonly arises from a mucinous
neoplasm of the appendix (Sugarbaker et al., 1996). Also, occasionally
this syndrome may arise from the colon or rectum, gallbladder, small
intestine, ovarian teratoma, lung, breast, pancreas, fallopian tube, and
urachus (Sugarbaker, 2012a). Described here are three patients pre-
sentingwithmucinous peritonealmetastases arising from an adenocar-
cinoma of the endocervix. This cause of this rare condition is unclear; it
may be caused by retrogrademenstruation. Evaluation of these patients
for cytoreductive surgery (CRS) and hyperthermic perioperative
chemotherapy (HIPEC) at a peritoneal surface oncology treatment
center early in the natural history of the disease is recommended., 106 Irving St., NW, Suite 3900,
garbaker).
. This is an open access article underUpper and lower gastrointestinal endoscopy was not revealing of a
cancerous process. She underwent a 9-hour complete CRS with greater
omentectomy, appendectomy, right upper quadrant peritonectomy,
lesser omentectomy, pelvic peritonectomy, hysterectomy, and bilateral
salpingo-oophorectomy (Sugarbaker, 2012b).
Pathology showed in-situ and invasivemucinous adenocarcinomaof
the endocervix with metastases to ovaries, fallopian tubes, omentum,
and peritoneum. The appendix was normal except for overlying extra-
cellular mucin. She was treated with HIPEC and early postoperative in-
traperitoneal chemotherapy (EPIC) (Sugarbaker, 2012b). The patient
was treated with a single cycle using cisplatin (50 mg/m2) and doxoru-
bicin (15 mg/m2) by intraperitoneal administration at 42 °C. Continu-
ous infusion intravenous ifosfamide was given over the 90 min of
HIPEC. Fifteen minutes prior to infusion 2-mercaptoethane sulfonate
NA (MESNA) at 260 mg/m2 was given as a bolus. The MESNA was re-
peated at 4 and 8 h after initiation of the HIPEC. Early postoperative in-
traperitoneal chemotherapy (EPIC) with paclitaxel at 20 mg/m2 in one
liter of 1.5% dextrose peritoneal dialysis solution was used postopera-
tive days one through ﬁve (Sugarbaker, 2012b). Systemic chemo-
therapy was given over ﬁve months using paclitaxel at 135 mg/m2
administered over 24 h on day one plus cisplatin 50 mg/m2 adminis-
tered on day two. Treatment was every 21 days for six cycles.
She remains asymptomatic on 6 monthly CT follow-up at 3 years.Patient presentation 2
In February of 2012, this 27 year old woman reported her ﬁrst
symptom as increasing inability to eat or drink. CT showed high jejunal
obstruction, a pelvic mass thought to be an enlarged ovary, and ascites.
Laparoscopy and dilatation and curettage with endocervical biopsy
showed adenocarcinoma from an invasive endocervical primary cancer.the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Fig. 1. Abdominal and pelvic CT on a patient with adenocarcinoma of the endocervix. Paracentesis resulted in the drainage of 10 l of ascites.
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AUC 4–7.5 was given every 21 days together with paclitaxel 175mg/m2
also every 21 days. Treatmentwas for six cycleswith good symptomatic
beneﬁt and a resumption of oral nutrition. In July of 2013, the patient
again became unable to eat and recurrent high jejunal obstruction was
conﬁrmed. At this time she underwent palliative surgery to bypass jeju-
nal and colonic obstructions. Greatly enlarged omentum and ovaries
were resected (Fig. 2). HIPEC was used in an attempt to control debili-
tating ascites (Sugarbaker, 2012b). HIPEC used cisplatin (50 mg/m2)
and doxorubicin (15 mg/m2) by intraperitoneal administration at
42 °C. Continuous infusion intravenous ifosfamide was given over the
90 min of HIPEC. Fifteen minutes prior to infusion 2-mercaptoethane
sulfonate NA (MESNA) at 260 mg/m2 was given as a bolus. The
MESNA was repeated at 4 and 8 h after initiation of the HIPEC. Early
postoperative intraperitoneal chemotherapy (EPIC) with paclitaxel at
20 mg/m2 in one liter of 1.5% dextrose peritoneal dialysis solution was
used postoperative days one through ﬁve (Sugarbaker, 2012b). All
biopsies and resected specimens were compatible with endocervical
adenocarcinoma. The left upper quadrant mass was not resected. She
was not thought to be a candidate for further systemic chemotherapy.
She died in October of 2013.
Patient presentation 3
This patient had Peutz–Jeghers syndrome and carried an STK-11
mutation. In January 2012 at age 44, she presented with vaginal
discharge. A hysterectomy showed a well differentiated mucinous
adenocarcinoma of the endocervix that fulﬁlled the criteria for minimal
deviation adenocarcinoma (‘adenomamalignum’) (McCluggage, 2013).Mucinous lesions were noted on the peritoneal surfaces, and a biopsy
showedmetastatic mucinous adenocarcinoma that wasmorphological-
ly similar to the cervical lesion. Immunohistochemistry showed expres-
sion of CK7 and CA125, but CK20 and CDX-2 were negative. Adjuvant
treatments with cisplatin at 40 mg/m2 for 5 weeks plus radiation ther-
apy to 45 Gy were given.
In 2013 she presented with pelvic pain and radiological features
of pseudomyxoma peritonei. There was signiﬁcant respiratory com-
promise as a result of a pulmonary embolism combined with massive
abdominal distention from ascites. It was decided to proceed to laparot-
omy following insertion of a vena cava ﬁlter and anticoagulation.
Laparotomy released 20 l of watery ascitic ﬂuid leading to improved
ventilation. Nodules of mucinous tumor were found on the small
bowel, on the under-surface of both diaphragms, in the paracolic gut-
ters, on the jejunum and the terminal ileum, and there was a massive
omental cake. Complete cytoreductionwas not possible and a debulking
procedure was performed, including total colectomy with end ileos-
tomy. HIPEC with mitomycin C at 20 mg/m2 at 42 °C for 90 min was
administered to help alleviate further ascites accumulation. Histology
of the tumor conﬁrmed metastatic mucinous adenocarcinoma (Fig. 3).
Her postoperative course was complicated by further deep venous
thromboses and she died on the 31st postoperative day.
Discussion
It is extremely uncommon for cervical cancer to be associated with
peritoneal metastases. Gatalica, Foster, and Loggie reported on low-
grade mucinous peritoneal metastases eight years after hysterectomy
in a patient who had cervical adenocarcinoma (Gatalica et al., 2008).
Fig. 2. Findings at the time of exploratory laparotomy in a patient with endocervical
adenocarcinoma. Top. The cystic left ovary was enlarged to 20 cm. The omentum was
diffusely inﬁltrated by tumor nodules. Bottom. Although a majority of the small bowel
was free of mucinous adenocarcinoma, mucinous cancer nodules at the junction of small
bowel and its mesentery caused partial obstruction at several sites.
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al metastases were identiﬁed. The peritoneal lesions tested positive for
high risk human papilloma virus, strongly suggesting abdominal and
pelvic cancer contamination at the time of hysterectomy as a cause of
the patient's peritoneal metastases.
The pathophysiology of cervical adenocarcinoma dissemination to
the peritoneal surfaces is not readily apparent. Recently, retrograde
menstruation from the fallopian tubes has been suggested to cause
what was previously identiﬁed as serous ovarian cancer (Kurman &
Shih, 2011). It is possible that adenocarcinoma cells from the endocervix
could likewise, in unusual patients, spread into the free peritoneal space
through a process of retrogrademenstruation. Two of our three patientsFig. 3. Peritoneal metastases from a patient with Peutz–Jeghers syndrome and
endocervical adenocarcinoma. The specimen was taken at the time of the surgery.were young and nulliparous. This is the patientwho ismost likely to de-
velop endometriosis, which is a manifestation of normal endometrial
tissue entering the peritoneal space through the process of retrograde
menstruation. Also, in all three of our patients there was extensive
mucus and serous ﬂuid produced by the malignancy leading to pro-
found abdominal distention in all three patients. The demonstrated abil-
ity of endocervical adenocarcinoma to produce such copious amounts of
ﬂuid seems well documented by our three patients. Copious slippery
ﬂuid discharged into the uterus may be forced into the fallopian tubes
and be expressed into the free peritoneal space. Of course, the ﬂuid
would be contaminated by mucinous cancer cells and would soon lead
to the extensive peritoneal metastases present in our patients.
Uterine perforation can result in direct inoculation of cancer cells
into the free peritoneal space. Anecdotal reports from the gynecologic
oncology literature document this fact. In 1981, Mills, Sugg, and
Mahnesmith reported the direct extension of a uterine adenosarcoma
through thewall of theuterus and growingout as a pelvicmass attached
to the uterine serosa (Mills et al., 1981). The cancer inside and outside of
the uterus was histologically identical. They identiﬁed this clinical situ-
ation as the ﬁrst reported example of direct inoculation of a cancer into
the peritoneal space following myometrial perforation. Levine et al.
noted trophoblastic tissue spread to the surface of the sigmoid colon
following uterine perforation during dilatation and curettage. A laparot-
omy showed trophoblastic tumor implants at the perforation site, ante-
rior uterine wall, and appendix epiploica of the sigmoid colon. Surgical
removal and treatment with methotrexate enabled the patient to re-
cover (Levin et al., 2004). A possible mechanism of dissemination
of endocervical adenocarcinoma into the free peritoneal cavity would
be uterine perforation at the time of a cervical dilatation and curettage.
However, no surgical record of uterine perforation was present in our
patients and the patients were not aware that such an event had
occurred.
The applications of CRS and HIPEC have been evolving and ex-
panding over the last 30 years. This combined treatment has been
shown to be of beneﬁt in themanagement of intraabdominal malignan-
cies, especially those having a high propensity for peritonealmetastases
(Glehen et al., 2010). Current data suggests that CRS and HIPEC should
be considered for appendicealmucinous neoplasmswith peritoneal dis-
semination, colon and rectal cancer with a small extent of peritoneal
metastases, and peritoneal mesothelioma. Also, patients with ovarian
cancer may be beneﬁted by complete CRS plus HIPEC as a ﬁrst line of
treatment or treatment for recurrent disease (Chua et al., 2009).
In this manuscript an uncommon application of CRS and HIPEC for
pseudomyxoma peritonei originating from endocervical adenocarcino-
ma was presented. To our knowledge this is the ﬁrst report of CRS and
HIPEC for endocervical adenocarcinoma with ovarian and peritoneal
metastases with the pseudomyxoma peritonei syndrome. Further clini-
cal studies are required to assess the durability of this approach to this
unusual manifestation of endocervical adenocarcinoma.
A survey of the surgical literature reveals that CRS and HIPEC have
been used to treat a variety of raremalignancies with peritoneal surface
dissemination (reviewed in Sugarbaker, 2012a). Usually, lowmalignant
potential (LMP) ovarian tumors carry an excellent prognosis. Unfortu-
nately, with long-term follow-up, a small spill of the minimally aggres-
sive tumor cells may progresswithin the peritoneal space to an extreme
size and become a terminal condition. Dermoid cysts of the ovary may
cause gliomatosis peritonei or mucinous peritoneal metastases and
the pseudomyxomaperitonei syndrome. A urachalmucinous adenocar-
cinoma may cause pseudomyxoma peritonei successfully treated by
CRS and HIPEC. Malignant pararectal hamartoma and perforated ma-
lignancy mesenteric cysts may cause pseudomyxoma peritonei and
be successfully treated by CRS and HIPEC. As a result of our successful
management of at least one patient, we suggest that patients who
have peritoneal metastases from endocervical adenocarcinoma be
evaluated by a center experienced in the treatment of peritoneal
surface malignancy.
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